COMMUNIQUÉS West-GlobeNewswire

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
08/04/2024
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted [...]
Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
08/04/2024
CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators [...]
MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES
08/04/2024
Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced the closing of its Amended and Restated Credit Agreement (the “Credit [...]
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
08/04/2024
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- INmune Bio, [...]
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
08/04/2024
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is [...]
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
08/04/2024
In combination with either atezolizumab or durvalumab MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical [...]
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
08/04/2024
MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic [...]
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
08/04/2024
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been [...]
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
08/04/2024
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will [...]
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
08/04/2024
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high [...]
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
08/04/2024
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 [...]
EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”
08/04/2024
MELBOURNE, Australia, April 08, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is [...]
Metagenomi to Present at Upcoming Scientific Meetings
08/04/2024
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EMERYVILLE, Calif [...]
Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
08/04/2024
Initial clinical data demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer. FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune ® Inc., a [...]
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
08/04/2024
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a [...]
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
08/04/2024
— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity — — Patient enrollment expected to be completed in 2024 — MELVILLE, N.Y., April 08, 2024 (GLOBE [...]
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
08/04/2024
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm ® has been administered to the first Parkinson’s [...]
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
08/04/2024
TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus [...]
XORTX Welcomes New Member to the Board of Directors
08/04/2024
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on [...]

Pages